Analytical Data
-
Gene name
MAGEA3
- Application
-
Alternative Names
Antigen MZ2-D (Cancer/testis antigen 1.3) (CT1.3) (MAGE-3 antigen) (MAGE3)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43357
-
Expression Region
1-314aa
-
Molecular Weight
39.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA3 (Melanoma Antigen Gene A3) is a member of the MAGE gene family, which encodes tumor-specific antigens typically expressed in various malignancies, including melanoma and certain other cancers. The protein is recognized for its role in immune response, particularly in eliciting T-cell responses in cancer immunotherapy. Research has shown that MAGEA3 is often overexpressed in tumor tissues while being absent in normal tissues, making it a promising target for cancer immunotherapy. In recent years, the interest in MAGEA3 recombinant protein has surged due to its potential use as a therapeutic agent and a biomarker for diagnosis and prognosis in cancer patients. By exploring the structural and functional properties of MAGEA3, scientists aim to develop novel vaccine strategies and adoptive T-cell therapies that can effectively harness the immune system to target and eradicate cancer cells expressing this antigen. Additionally, studies have indicated that MAGEA3 may play a role in tumor progression and immune evasion, underscoring its importance in the broader context of tumor biology. As research progresses, the characterization of MAGEA3 recombinant protein could lead to significant advancements in targeted cancer therapies and enhanced patient outcomes.
